DK1497266T3 - Quinolinderivater og deres anvendelse som 5HT6-ligander - Google Patents

Quinolinderivater og deres anvendelse som 5HT6-ligander

Info

Publication number: DK1497266T3
Authority: DK; Denmark
Prior art keywords: ligands; quinoline derivatives; quinoline; derivatives
Prior art date: 2002-03-27

Application number

DK03714889T

Other languages

English (en)

Inventor

Christopher Norbert Johnson

Martin C Jones

Gregor James Macdonald

Charles Edward Wade

David Witty

Mahmood Ahmed

Stephen Frederick Moss

Mervyn Thompson

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-27

Filing date

2003-03-25

Publication date

2008-10-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28456035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1497266(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-03-27 Priority claimed from GB0207289A external-priority patent/GB0207289D0/en

2002-11-04 Priority claimed from GB0225678A external-priority patent/GB0225678D0/en

2003-03-25 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2008-10-06 Application granted granted Critical

2008-10-06 Publication of DK1497266T3 publication Critical patent/DK1497266T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Obesity (AREA)
Immunology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Anesthesiology (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Quinoline Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK03714889T 2002-03-27 2003-03-25 Quinolinderivater og deres anvendelse som 5HT6-ligander DK1497266T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0207289A GB0207289D0 (en)	2002-03-27	2002-03-27	Novel compounds
GB0225678A GB0225678D0 (en)	2002-11-04	2002-11-04	Novel compounds
PCT/EP2003/003197 WO2003080580A2 (en)	2002-03-27	2003-03-25	Quinoline derivatives and their use as 5-ht6 ligands

Publications (1)

Publication Number	Publication Date
DK1497266T3 true DK1497266T3 (da)	2008-10-06

Family

ID=28456035

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK03714889T DK1497266T3 (da)	2002-03-27	2003-03-25	Quinolinderivater og deres anvendelse som 5HT6-ligander
DK08157490.7T DK1956004T3 (da)	2002-03-27	2003-03-25	Quinolinderivater og deres anvendelse som 5-HT6-ligander

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK08157490.7T DK1956004T3 (da)	2002-03-27	2003-03-25	Quinolinderivater og deres anvendelse som 5-HT6-ligander

Country Status (28)

Country	Link
US (5)	US7452888B2 (da)
EP (2)	EP1497266B1 (da)
JP (2)	JP4455064B2 (da)
KR (1)	KR101020399B1 (da)
CN (1)	CN1315809C (da)
AR (1)	AR039127A1 (da)
AT (1)	ATE398108T1 (da)
AU (1)	AU2003219103B2 (da)
BR (1)	BRPI0308696B8 (da)
CA (1)	CA2479786C (da)
CY (2)	CY1108313T1 (da)
DE (1)	DE60321558D1 (da)
DK (2)	DK1497266T3 (da)
ES (2)	ES2386828T3 (da)
HK (1)	HK1074439A1 (da)
IL (2)	IL164108A0 (da)
IS (1)	IS2599B (da)
MX (1)	MXPA04009318A (da)
MY (1)	MY138836A (da)
NO (1)	NO329319B1 (da)
NZ (1)	NZ535239A (da)
PL (1)	PL209872B1 (da)
PT (2)	PT1956004E (da)
RU (1)	RU2309154C9 (da)
SI (2)	SI1497266T1 (da)
TW (1)	TWI268928B (da)
WO (1)	WO2003080580A2 (da)
ZA (1)	ZA200407320B (da)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2003219103B2 (en) *	2002-03-27	2008-10-23	Axovant Sciences Gmbh	Quinoline derivatives and their use as 5-HT6 ligands
KR20050101551A (ko)	2003-02-14	2005-10-24	와이어쓰	5-하이드록시트립타민-6 리간드로서의헤테로사이클릴-3-설포닐인다졸
CA2515571A1 (en)	2003-02-14	2004-09-02	Wyeth	Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
TW200523253A (en)	2003-07-22	2005-07-16	Arena Pharm Inc	Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
GB0320320D0 (en) *	2003-08-29	2003-10-01	Glaxo Group Ltd	Novel compounds
GB0321473D0 (en) *	2003-09-12	2003-10-15	Glaxo Group Ltd	Novel compounds
GB0322510D0 (en)	2003-09-25	2003-10-29	Glaxo Group Ltd	Novel compounds
PT1667975E (pt) *	2003-09-26	2008-02-29	Glaxo Group Ltd	Forma polimórfica de 3-fenilsulfonil-8-piperazin-1-il-quinolina
GB0407025D0 (en) *	2004-03-29	2004-04-28	Glaxo Group Ltd	Novel compounds
GB0411421D0 (en) *	2004-05-21	2004-06-23	Glaxo Group Ltd	Novel compounds
GB0425548D0 (en) *	2004-11-19	2004-12-22	Glaxo Group Ltd	Radiolabelled ligands
GB0426313D0 (en) *	2004-12-01	2005-01-05	Merck Sharp & Dohme	Therapeutic agents
CA2610456A1 (en)	2005-06-02	2006-12-07	F. Hoffmann-La Roche Ag	3-methanesulfonylquinolines as gaba-b enhancers
CA2616473A1 (en) *	2005-07-27	2007-03-08	F. Hoffmann-La Roche Ag	4-aryloxy quinoline derivatives as 5-ht6 modulators
GB0519765D0 (en) *	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel compounds
GB0519760D0 (en) *	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel compounds
GB0519758D0 (en) *	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel process
EP1962849B1 (en) *	2005-12-20	2009-09-30	Richter Gedeon NYRT	Quinoline derivatives useful in the treatment of mglur5 receptor-mediated disorders
MX2008012824A (es)	2006-04-05	2008-10-15	Wyeth Corp	Derivados de sulfonil-3-heterociclilindazol como ligandos de 5-hidroxitriptamina-6.
BRPI0718737A2 (pt)	2007-01-08	2014-03-25	Suven Life Sciences Ltd	"composto, processo para a preparação de um composto, método para o tratamento de uma desordem do sistema nervoso central, composição farmacêutica, uso do composto, método para testar antagonistas e antagonistas com seletividade para o receptor 5-ht6, e método de tratamento"
UA100684C2 (uk) *	2007-03-15	2013-01-25	Новартіс Аг	Похідні бензилу та піридинілу як модулятори сигнального шляху hedgehog
ES2389958T3 (es) *	2007-03-21	2012-11-05	Glaxo Group Limited	Uso de derivados de quinolina en el tratamiento del dolor
MX2009010243A (es) *	2007-03-23	2009-12-14	Abbott Gmbh & Co Kg	Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6.
BRPI0809873A2 (pt)	2007-05-03	2018-11-13	Suven Life Sciences Ltd	"composto, processo para a preparação do composto, método para o tratamento de uma desordem do sistema nervoso central, composição farmacêutica, uso do composto, método para testar antagonistas e antagonistas com seletividade para o receptor 5-th6 e método de tratamento"
JP5543917B2 (ja) *	2007-06-18	2014-07-09	リヒターゲデオンニルバーノシャンミーケデーレスベニュタールシャシャーグ	スルホニル−キノリン誘導体
BRPI0812853A2 (pt) *	2007-08-07	2014-12-23	Abbott Gmbh	Compostos de quinolina adequados para tratar distúrbios que respondem à modulação do receptor 5-ht6 de serotonina.
WO2009053997A1 (en)	2007-10-26	2009-04-30	Suven Life Sciences Limited	Amino arylsulfonamide compounds and their use as 5-ht6 ligands
US9084742B2 (en) *	2007-12-12	2015-07-21	Axovant Sciences Ltd.	Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
JP2011512340A (ja) *	2008-02-15	2011-04-21	エフ．ホフマン−ラロシュアーゲー	３−アルキルピペラジン誘導体及びその使用
US20110021538A1 (en)	2008-04-02	2011-01-27	Arena Pharmaceuticals, Inc.	Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US20100041663A1 (en)	2008-07-18	2010-02-18	Novartis Ag	Organic Compounds as Smo Inhibitors
WO2010032257A1 (en)	2008-09-17	2010-03-25	Suven Life Sciences Limited	Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands
EP2346847B1 (en)	2008-09-17	2013-05-15	Suven Life Sciences Limited	Aryl sulfonamide amine compounds and their use as 5-ht6 ligands
US9126946B2 (en)	2008-10-28	2015-09-08	Arena Pharmaceuticals, Inc.	Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
SG177434A1 (en)	2009-06-29	2012-02-28	Agios Pharmaceuticals Inc	Therapeutic compounds and compositions
PL2522658T3 (pl) *	2010-01-04	2019-01-31	Nippon Soda Co., Ltd.	Zawierający azot związek heterocykliczny i rolniczy/ogrodniczy środek drobnoustrojobójczy
DK2521714T3 (da)	2010-01-05	2015-10-19	Suven Life Sciences Ltd	Aromatiske sulfonsammensætninger nyttige ved behandling af centralnervesygdomme
RU2443697C1 (ru) *	2010-12-21	2012-02-27	Александр Васильевич Иващенко	Замещенные метил-амины, антагонисты серотониновых 5-ht6 рецепторов, способы получения и применения
KR101250606B1 (ko) *	2011-01-24	2013-04-03	이화여자대학교 산학협력단	5-ｈｔ６ 수용체 억제 작용을 갖는 신규한 벤조티아졸 및 벤즈이소티아졸유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
AR086411A1 (es)	2011-05-20	2013-12-11	Nippon Soda Co	Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria
EP2763676B1 (en)	2011-10-03	2019-12-25	The University of Utah Research Foundation	Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
RU2500672C1 (ru) *	2012-10-25	2013-12-10	Андрей Александрович Иващенко	(3-арилсульфонилхинолин-8-ил)-диалкил-амины - селективные антагонисты серотониновых 5-ht6 рецепторов, способы их получения и применения
US9302992B2 (en)	2013-04-02	2016-04-05	Annji Pharmaceutical Co., Ltd.	Multifunctional quinoline derivatives as anti-neurodegenerative agents
CN105452224B (zh)	2013-04-02	2017-12-26	安基生技新药股份有限公司	作为抗神经退化剂的多官能性喹啉衍生物
WO2016179569A1 (en) *	2015-05-07	2016-11-10	Axovant Sciences Ltd.	Compositions and methods of treating a neurodegenerative disease
RU2017145976A (ru)	2015-06-12	2019-07-15	Аксовант Сайенсиз Гмбх	Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
CN108472285A (zh)	2015-07-15	2018-08-31	阿速万科学有限责任公司	用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物
AR106515A1 (es) *	2015-10-29	2018-01-24	Bayer Cropscience Ag	Sililfenoxiheterociclos trisustituidos y análogos
JP7027318B2 (ja) *	2016-02-05	2022-03-01	ファーネクスト	神経障害の新規の併用療法
US10160744B2 (en)	2016-03-14	2018-12-25	AbbVie Deutschland GmbH & Co. KG	Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-HT6 receptor
WO2017202206A1 (zh) *	2016-05-27	2017-11-30	深圳市塔吉瑞生物医药有限公司	一种取代的喹啉化合物及其药物组合物
WO2018102824A1 (en) *	2016-12-02	2018-06-07	Axovant Sciences Gmbh	Methods for treating neurodegenerative disease
KR20210076224A (ko)	2019-12-13	2021-06-24	주식회사 에피바이오텍	퀴놀린 유도체를 포함하는 탈모의 예방 또는 치료용 조성물
KR102281647B1 (ko) *	2020-12-09	2021-07-30	메디케어제약 주식회사	피페라진-퀴놀린 유도체의 제조방법

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US708469A (en) *	1901-08-27	1902-09-02	George Lafayette Caldwell	Stroke-regulating mechanism for glass-presses, &c.
JPH02262627A (ja)	1988-12-08	1990-10-25	Japan Synthetic Rubber Co Ltd	有機非線形光学素子
SI9200377A (en) *	1992-12-11	1994-06-30	Krka	Process for the preparation of 1-substituted 6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydroquinoline-3-carboxilic acid, novel intermediate used in this process and process for its preparation
GB9300147D0 (en)	1993-01-06	1993-03-03	Minnesota Mining & Mfg	Photothermographic materials
GB9311790D0 (en)	1993-06-08	1993-07-28	Minnesota Mining & Mfg	Photothermographic materials
US5596001A (en) *	1993-10-25	1997-01-21	Pfizer Inc.	4-aryl-3-(heteroarylureido)quinoline derivatves
DK122693D0 (da)	1993-10-29	1993-10-29	Hempels Skibsfarve Fab J C	Marin struktur
US5576338A (en) *	1995-02-15	1996-11-19	Merck Frosst Canada, Inc.	Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis
AUPN842196A0 (en)	1996-03-05	1996-03-28	Fujisawa Pharmaceutical Co., Ltd.	New compound
FR2750988B1 (fr)	1996-07-11	1998-09-18	Adir	Nouveaux derives de 2-(1h)-quinoleinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DZ2376A1 (fr) *	1996-12-19	2002-12-28	Smithkline Beecham Plc	Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
US20010051719A1 (en) *	1996-12-19	2001-12-13	Smithkline Beecham P.L.C.	Novel compounds
DE59803962D1 (de)	1997-03-25	2002-06-06	Ciba Sc Holding Ag	Polycyclische Verbindungen
AU7644698A (en)	1997-04-22	1998-11-13	Janssen Pharmaceutica N.V.	Crf antagonistic quino- and quinazolines
WO1998054156A1 (en)	1997-05-28	1998-12-03	Rhone-Poulenc Rorer Pharmaceuticals, Inc.	QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES
US6103905A (en)	1997-06-19	2000-08-15	Sepracor, Inc.	Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6207679B1 (en) *	1997-06-19	2001-03-27	Sepracor, Inc.	Antimicrobial agents uses and compositions related thereto
US6376670B1 (en) *	1997-06-19	2002-04-23	Sepracor Inc.	Quinoline-indole antimicrobial agents, uses and compositions related thereto
AU757059B2 (en) *	1997-06-19	2003-01-30	Sepracor, Inc.	Quinoline-indole antimicrobial agents, uses and compositions related thereto
KR20010021643A (ko)	1997-07-11	2001-03-15	피터 기딩스	5-ｈｔ6수용체길항제인술폰아미드유도체및그의제조방법
PT930302E (pt) *	1998-01-16	2003-07-31	Hoffmann La Roche	Derivados de benzo-sulfona
GB9801392D0 (en) *	1998-01-22	1998-03-18	Smithkline Beecham Plc	Novel compounds
GB9803411D0 (en)	1998-02-18	1998-04-15	Smithkline Beecham Plc	Novel compounds
US6100291A (en)	1998-03-16	2000-08-08	Allelix Biopharmaceuticals Inc.	Pyrrolidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) *	1998-06-15	2001-06-26	Nps Allelix Corp.	Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
GB9818916D0 (en) *	1998-08-28	1998-10-21	Smithkline Beecham Plc	Use
GB9819382D0 (en)	1998-09-04	1998-10-28	Cerebrus Ltd	Chemical compounds I
GB9820113D0 (en) *	1998-09-15	1998-11-11	Merck Sharp & Dohme	Therapeutic agents
US6403808B1 (en) *	1999-12-10	2002-06-11	Virginia Commonwealth University	Selective 5-HT6 receptor ligands
AU3033500A (en)	1999-01-15	2000-08-01	Agouron Pharmaceuticals, Inc.	Non-peptide glp-1 agonists
CA2368455A1 (en)	1999-03-29	2000-10-05	Neurogen Corporation	4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands
EP1173432B9 (en) *	1999-04-21	2008-10-15	NPS Allelix Corp.	Piperidine-indole compounds having 5-ht6 affinity
WO2000064877A1 (en)	1999-04-26	2000-11-02	Neurogen Corporation	2-aminoquinolinecarboxamides: neurokinin receptor ligands
US6566372B1 (en)	1999-08-27	2003-05-20	Ligand Pharmaceuticals Incorporated	Bicyclic androgen and progesterone receptor modulator compounds and methods
MY125942A (en)	1999-09-07	2006-09-29	Upjohn Co	Aminoalkoxy carbazoles for the treatment of cns diseases
GB9926302D0 (en) *	1999-11-05	2000-01-12	Smithkline Beecham Plc	Novel compounds
AU1542201A (en)	1999-11-05	2001-05-14	Nps Allelix Corp.	Compounds having 5-HT6 receptor antagonist activity
UA75055C2 (uk)	1999-11-30	2006-03-15	Пфайзер Продактс Інк.	Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
US6310212B1 (en) *	2000-03-28	2001-10-30	Neurogen Corporation	4-substituted quinoline derivatives
PE20020063A1 (es)	2000-06-20	2002-01-30	Upjohn Co	Bis-arilsulfonas como ligandos del receptor de 5-ht
SE0002754D0 (sv)	2000-07-21	2000-07-21	Pharmacia & Upjohn Ab	New pharmaceutical combination formulation and method of treatment with the combination
GB0021450D0 (en)	2000-08-31	2000-10-18	Smithkline Beecham Plc	Novel compounds
US6576644B2 (en)	2000-09-06	2003-06-10	Bristol-Myers Squibb Co.	Quinoline inhibitors of cGMP phosphodiesterase
ES2309095T3 (es)	2000-10-02	2008-12-16	Janssen Pharmaceutica Nv	Antagonistas de los receptores metabotropicos de glutamato.
KR100823908B1 (ko)	2000-10-20	2008-04-21	바이오비트럼 에이비(피유비엘)	2-, 3-, 4-, 또는 5-치환-ｎ1-(벤젠술포닐)인돌 및 이의치료 용도
AU2002220051B2 (en)	2000-11-02	2007-05-24	Wyeth	1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
EP1341783A1 (en)	2000-11-21	2003-09-10	Smithkline Beecham Plc	Isoquinoline derivatives useful in the treatment of cns disorders
EP1335722B1 (en)	2000-11-24	2006-08-30	Smithkline Beecham Plc	Indolyl-sulfonyl- compounds useful in the treatment of cns disorders
ES2188344B1 (es)	2000-11-29	2004-09-16	Laboratorios Vita, S.A.	Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos.
GB0111186D0 (en)	2001-05-08	2001-06-27	Smithkline Beecham Plc	Novel compounds
KR100600240B1 (ko)	2001-06-07	2006-07-13	에프. 호프만-라 로슈 아게	5-ｈｔ6 수용체 친화도를 갖는 신규한 인돌 유도체
CA2450245A1 (en)	2001-06-15	2002-12-27	F. Hoffmann-La Roche Ag	4-piperazinylindole derivatives with 5-ht6 receptor affinity
ITRM20010356A1 (it) *	2001-06-21	2002-12-23	Sigma Tau Ind Farmaceuti	"5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
WO2003011284A1 (en)	2001-08-03	2003-02-13	Pharmacia & Upjohn Company	5-arylsulfonyl indoles having 5-ht6 receptor affinity
JP2005527463A (ja)	2001-08-07	2005-09-15	スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー	Ｃｎｓ疾患を治療するための５−ｈｔ６受容体アフィニティーを有する３−アリールスルホニル−７−ピペラジニル−インドール、−ベンゾフランおよび−ベンゾチオフェン
ATE417838T1 (de)	2001-08-10	2009-01-15	Hoffmann La Roche	Arylsulfonyl-derivate mit 5-ht 6-rezeptor- affinität
PT1425272E (pt)	2001-08-31	2011-10-19	Novartis Ag	Isómeros óticos de um metabolito de iloperidona
SE0103649D0 (sv)	2001-11-01	2001-11-01	Astrazeneca Ab	Therapeutic quinoline compounds
JP2005518414A (ja)	2001-12-21	2005-06-23	スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー	ドーパミン受容体のモジュレーターとしての７−スルホニル−３−ベンゾアゼピン誘導体およびｃｎｓ障害の治療のためのその使用
GB0202679D0 (en) *	2002-02-05	2002-03-20	Glaxo Group Ltd	Novel compounds
WO2003066056A1 (en)	2002-02-05	2003-08-14	Glaxo Group Limited	Method of promoting neuronal growth
ATE323680T1 (de) *	2002-02-13	2006-05-15	Glaxo Group Ltd	7-arylsulfonamid-2,3,4,5-tetrahydro-1h- benzo¬däazepine mit 5-ht6 rezeptor affinität zur behandlung von zentralnervensystemerkrankungen
DE10207844A1 (de)	2002-02-15	2003-09-04	Schering Ag	1-Phenyl-2-heteroaryl-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
EP1478361A2 (en)	2002-02-22	2004-11-24	PHARMACIA & UPJOHN COMPANY	Arylsulfone derivatives
AU2003219103B2 (en) *	2002-03-27	2008-10-23	Axovant Sciences Gmbh	Quinoline derivatives and their use as 5-HT6 ligands
DE60309852T2 (de)	2002-03-27	2007-06-06	Glaxo Group Ltd., Greenford	Chinolin- und aza-indolderivate und deren verwendung als 5-ht6 liganden
KR100636475B1 (ko)	2002-05-13	2006-10-18	에프. 호프만-라 로슈 아게	5-ｈｔ6 조절제로서 벤족사진 유도체 및 이의 용도
DE10221183A1 (de)	2002-05-13	2003-12-04	Max Planck Gesellschaft	Phosphatidyl-oligo-glycerine und Strukturanaloga
EP1513809A1 (en)	2002-06-05	2005-03-16	F. Hoffmann-La Roche Ag	1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders
RS111204A (en)	2002-06-20	2006-12-15	Biovitrum Ab.	New compounds useful for the treatment of obesity,type ii diabetes and cns disorders
JP4754821B2 (ja) *	2002-06-20	2011-08-24	プロキシマゲン・リミテッド	肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
CA2498946A1 (en)	2002-09-17	2004-04-01	F. Hoffmann-La Roche Ag	2,4-substituted indoles and their use as 5-ht6 modulators
NZ537982A (en)	2002-09-17	2007-05-31	Hoffmann La Roche	2,7-substituted indoles and their use as 5-HT6 modulators
KR20050073560A (ko)	2002-10-18	2005-07-14	에프. 호프만-라 로슈 아게	5-ｈｔ6 수용체 친화성을 갖는 4-피페라진일 벤젠설폰일인돌
TWI285639B (en)	2002-11-08	2007-08-21	Roche Palo Alto Llc	Substituted benzoxazinones and uses thereof
CN1713908B (zh) *	2002-12-03	2010-05-12	弗·哈夫曼-拉罗切有限公司	作为5-ht6-受体配体用于治疗中枢神经系统病症的氨基烷氧基吲哚
CA2515571A1 (en) *	2003-02-14	2004-09-02	Wyeth	Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
KR100751604B1 (ko)	2003-03-03	2007-08-22	에프. 호프만-라 로슈 아게	5-ｈｔ6 조절자로서 사용되는 2,5- 및 2,6-치환된테트라하이드로아이소퀴놀린
TWI289141B (en)	2003-03-11	2007-11-01	Hoffmann La Roche F. Ag.	Quinolinone derivatives and uses thereof
GB0305575D0 (en) *	2003-03-11	2003-04-16	Glaxo Group Ltd	Novel compounds
GB0320320D0 (en)	2003-08-29	2003-10-01	Glaxo Group Ltd	Novel compounds
GB0321473D0 (en)	2003-09-12	2003-10-15	Glaxo Group Ltd	Novel compounds
GB0322510D0 (en)	2003-09-25	2003-10-29	Glaxo Group Ltd	Novel compounds
PT1667975E (pt)	2003-09-26	2008-02-29	Glaxo Group Ltd	Forma polimórfica de 3-fenilsulfonil-8-piperazin-1-il-quinolina
GB0407025D0 (en)	2004-03-29	2004-04-28	Glaxo Group Ltd	Novel compounds
GB0411421D0 (en)	2004-05-21	2004-06-23	Glaxo Group Ltd	Novel compounds
GB0422263D0 (en)	2004-10-07	2004-11-10	Glaxo Group Ltd	Novel compounds
GB0519760D0 (en)	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel compounds
GB0519765D0 (en)	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel compounds

2003
- 2003-03-25 AU AU2003219103A patent/AU2003219103B2/en not_active Ceased
- 2003-03-25 WO PCT/EP2003/003197 patent/WO2003080580A2/en active IP Right Grant
- 2003-03-25 CA CA2479786A patent/CA2479786C/en not_active Expired - Fee Related
- 2003-03-25 SI SI200331326T patent/SI1497266T1/sl unknown
- 2003-03-25 IL IL16410803A patent/IL164108A0/xx unknown
- 2003-03-25 DK DK03714889T patent/DK1497266T3/da active
- 2003-03-25 PL PL374378A patent/PL209872B1/pl unknown
- 2003-03-25 TW TW092106558A patent/TWI268928B/zh not_active IP Right Cessation
- 2003-03-25 AR ARP030101028A patent/AR039127A1/es not_active Application Discontinuation
- 2003-03-25 PT PT08157490T patent/PT1956004E/pt unknown
- 2003-03-25 DK DK08157490.7T patent/DK1956004T3/da active
- 2003-03-25 EP EP03714889A patent/EP1497266B1/en not_active Expired - Lifetime
- 2003-03-25 KR KR1020047015297A patent/KR101020399B1/ko active IP Right Grant
- 2003-03-25 SI SI200332178T patent/SI1956004T1/sl unknown
- 2003-03-25 ES ES08157490T patent/ES2386828T3/es not_active Expired - Lifetime
- 2003-03-25 MX MXPA04009318A patent/MXPA04009318A/es active IP Right Grant
- 2003-03-25 DE DE60321558T patent/DE60321558D1/de not_active Expired - Lifetime
- 2003-03-25 US US10/509,078 patent/US7452888B2/en not_active Expired - Lifetime
- 2003-03-25 JP JP2003578335A patent/JP4455064B2/ja not_active Expired - Fee Related
- 2003-03-25 PT PT03714889T patent/PT1497266E/pt unknown
- 2003-03-25 EP EP08157490A patent/EP1956004B1/en not_active Expired - Lifetime
- 2003-03-25 NZ NZ535239A patent/NZ535239A/en not_active IP Right Cessation
- 2003-03-25 MY MYPI20031054A patent/MY138836A/en unknown
- 2003-03-25 AT AT03714889T patent/ATE398108T1/de active
- 2003-03-25 CN CNB038116448A patent/CN1315809C/zh not_active Expired - Fee Related
- 2003-03-25 RU RU2004131641/04A patent/RU2309154C9/ru not_active IP Right Cessation
- 2003-03-25 ES ES03714889T patent/ES2307919T3/es not_active Expired - Lifetime
- 2003-03-25 BR BRPI0308696A patent/BRPI0308696B8/pt not_active IP Right Cessation
2004
- 2004-09-13 ZA ZA2004/07320A patent/ZA200407320B/en unknown
- 2004-09-14 IL IL164108A patent/IL164108A/en not_active IP Right Cessation
- 2004-09-24 IS IS7470A patent/IS2599B/is unknown
- 2004-10-25 NO NO20044588A patent/NO329319B1/no not_active IP Right Cessation
2005
- 2005-06-29 HK HK05105458A patent/HK1074439A1/xx not_active IP Right Cessation
2008
- 2008-09-03 CY CY20081100943T patent/CY1108313T1/el unknown
- 2008-09-05 US US12/205,079 patent/US7601837B2/en not_active Expired - Fee Related
2009
- 2009-05-25 JP JP2009125459A patent/JP5091913B2/ja not_active Expired - Fee Related
- 2009-08-14 US US12/541,456 patent/US7799774B2/en not_active Expired - Fee Related
2010
- 2010-07-30 US US12/847,039 patent/US7977337B2/en not_active Expired - Fee Related
2011
- 2011-06-03 US US13/152,356 patent/US8236947B2/en not_active Expired - Fee Related
2012
- 2012-09-05 CY CY20121100804T patent/CY1113306T1/el unknown

Also Published As

Publication number	Publication date
JP5091913B2 (ja)	2012-12-05
US7977337B2 (en)	2011-07-12
US8236947B2 (en)	2012-08-07
US20110237792A1 (en)	2011-09-29
JP4455064B2 (ja)	2010-04-21
BRPI0308696B1 (pt)	2019-07-16
WO2003080580A2 (en)	2003-10-02
BRPI0308696B8 (pt)	2021-05-25
SI1497266T1 (sl)	2008-10-31
DE60321558D1 (de)	2008-07-24
IS7470A (is)	2004-09-24
PL374378A1 (en)	2005-10-17
IS2599B (is)	2010-04-15
BR0308696A (pt)	2005-01-25
US7452888B2 (en)	2008-11-18
WO2003080580A3 (en)	2004-02-05
CY1113306T1 (el)	2016-04-13
NZ535239A (en)	2008-03-28
AR039127A1 (es)	2005-02-09
ATE398108T1 (de)	2008-07-15
RU2309154C9 (ru)	2016-09-27
CN1656075A (zh)	2005-08-17
TW200403224A (en)	2004-03-01
PT1956004E (pt)	2012-08-31
IL164108A (en)	2010-05-31
MXPA04009318A (es)	2005-01-25
US20050124628A1 (en)	2005-06-09
NO329319B1 (no)	2010-09-27
ES2307919T3 (es)	2008-12-01
NO20044588L (no)	2004-10-25
EP1497266A2 (en)	2005-01-19
JP2009235080A (ja)	2009-10-15
SI1956004T1 (sl)	2012-09-28
EP1956004A1 (en)	2008-08-13
US7601837B2 (en)	2009-10-13
PL209872B1 (pl)	2011-10-31
IL164108A0 (en)	2005-12-18
EP1497266B1 (en)	2008-06-11
EP1956004B1 (en)	2012-06-13
MY138836A (en)	2009-07-31
CA2479786C (en)	2011-11-29
RU2309154C2 (ru)	2007-10-27
DK1956004T3 (da)	2012-08-06
US20090036682A1 (en)	2009-02-05
ES2386828T3 (es)	2012-08-31
AU2003219103A1 (en)	2003-10-08
KR20040094874A (ko)	2004-11-10
CY1108313T1 (el)	2014-02-12
RU2004131641A (ru)	2005-06-27
CA2479786A1 (en)	2003-10-02
TWI268928B (en)	2006-12-21
US7799774B2 (en)	2010-09-21
US20100305107A1 (en)	2010-12-02
BRPI0308696A8 (pt)	2017-04-11
US20090298841A1 (en)	2009-12-03
PT1497266E (pt)	2008-09-10
JP2005531518A (ja)	2005-10-20
AU2003219103B2 (en)	2008-10-23
HK1074439A1 (en)	2005-11-11
ZA200407320B (en)	2005-11-30
KR101020399B1 (ko)	2011-03-08
CN1315809C (zh)	2007-05-16

Publication	Publication Date	Title
DK1497266T3 (da)	2008-10-06	Quinolinderivater og deres anvendelse som 5HT6-ligander
DK1527050T3 (da)	2010-07-19	Quinolin-derivater og deres anvendelse som mycobakterielle inhibitorer
DK1480955T3 (da)	2007-10-29	O-cyclopropyl-carboxanilider og deres anvendelse som fungicider
DK1478629T3 (da)	2007-01-29	N-aryl-2-oxazolidinon-5-carboxamider og deres derivater og deres anvendelse som antibakterielle midler
ATE478870T1 (de)	2010-09-15	Spiroindolinpiperidinderivate
ATE460418T1 (de)	2010-03-15	Heterocyclocarboxamidderivate
ATE450506T1 (de)	2009-12-15	Indol-3-schwefelderivate
ATE467631T1 (de)	2010-05-15	Chinuclidinamidderivate
IS8439A (is)	2006-05-04	Nýjar kínólín afleiður
DK2248807T3 (da)	2013-08-26	N-Phenyl-2-pyrimidinaminderivater
IS6934A (is)	2003-08-29	Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
ATE438628T1 (de)	2009-08-15	Pyridazinderivate
ATE481402T1 (de)	2010-10-15	Pyrazolopyridin-derivate
DK1558615T3 (da)	2007-12-03	Purin-forbindelser og deres anvendelse som cannabinoid receptor ligander
DK1456206T3 (da)	2008-09-08	Azaindolylalkylaminderivater som 5-hydroxytryptamin-6-ligander
IS8180A (is)	2005-12-14	Nýjar besímídasólafleiður
DK1455779T3 (da)	2006-10-30	Indolylalkylaminderivater som 5-hydroxytryptamin-6-ligander
NO20043580D0 (no)	2004-08-27	Quinazolinonderivater og deres bruk som CB agonister
DE60307512D1 (de)	2006-09-21	3h-chinazoline -4-on derivaten
DK1663982T3 (da)	2008-03-17	Aminoquinolinderivater og deres anvendelse som adenosin-A3-ligander
DK1387838T3 (da)	2006-08-14	Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
DE60304516D1 (de)	2006-05-24	Fritiergerät
DE60323910D1 (de)	2008-11-20	Fritiergerät
DE50306277D1 (de)	2007-02-22	4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
DE60311233D1 (de)	2007-03-08	Chinolinderivate